Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
engineered anti-EpCAM IgA antibody
- Development stage
- Preclinical
- Lead developer
- Radboud University Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
The engineered anti-EpCAM IgA antibody is an investigational IgA-class monoclonal antibody designed to target Epithelial Cell Adhesion Molecule (EpCAM, CD326), a protein highly overexpressed on various carcinomas and epithelial cancers. Developed by the Radboud University Medical Center (Radboudumc), this antibody utilizes the IgA isotype to engage myeloid immune effector cells, such as neutrophils and macrophages, which express the FcαRI receptor. This engagement triggers tumor cell destruction via antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). It is being evaluated in ex vivo translational research studies using blood from healthy volunteers to assess its efficacy in tumor-killing assays, both alone and in combination with other immunotherapies or checkpoint inhibitors.
- Other names
- anti-EpCAM IgA antibodyengineered IgA antibody against EpCAM
02
Targets
FCAR (Fc alpha receptor I)EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on engineered anti-EpCAM IgA antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on engineered anti-EpCAM IgA antibody.